The 2010 Investment U Conference is underway! And even if you couldn't make it, now you can "bring home" more than 30 breakthrough presentations from the conference... Order the Deluxe MP3/Video Library for $99 to listen and view on your computer, or the Premier CD plus MP3/Video Library for $149 to listen to and view anywhere.
by The Investment U Research Team
In an interesting footnote to the Pizza wars, Papa Johns (Nasdaq: PZZA) has decided not to expand its offerings into pasta and non-core pizza items.
We approve of the move to focus on their primary offerings and concerns over keeping product quality up. That kind of management focus and discipline will equate to bottom line profits.
Number one and two competitors, Pizza Hut (NYSE: YUM) and Domino’s (NYSE: DPZ), are looking to broaden their offerings by adding pastas, chicken wings and sandwich items.
And that makes sense for a brand like Pizza Hut, which has lots of eat-in restaurants. It needs to expand its brand appeal and revamp a tired image.
On the other hand, Domino’s time and money might be better spent improving the advertising and public perception instead of straying from their core products. It reminds us of the same issues Subway struggled with.
Subway started trying to be all things to all customers – adding exotic sandwiches and a variety of options – and the biggest effect was that it started missing the mark on its core products. Only now is Subway starting to correct that and cut down its menu offerings.
Domino’s could learn a thing or two from Subway on improving their core products, or they might look across the street to Papa Johns. Papa John seems to have things well under control.
Symbols mentioned in this article: PZZA, YUM and DPZ.
- Penske Picks up “Belle” of GM
- What Nestle Wants, Nestle Gets… And Right Now, Nestle Wants a Bigger Slice of the Pie
- The U.S. Automakers: A Slow Motion Disaster
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
Investment U RSS Feed